The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 5, 2010, Pages 326-331

  Pooya, Sh ^a   Jalali, M Djalali ^a   Jazayery, A Djazayery ^a   Saedisomeolia, A ^a   Eshraghian, M Reza ^a   Toorang, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; Homocysteine; Malondialdehyde; Omega 3 fatty acid; Type II diabetes

Indexed keywords

C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HOMOCYSTEINE; MALONALDEHYDE; OMEGA 3 FATTY ACID;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; MALONDIALDEHYDE; MIDDLE AGED;

EID: 77956654768     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.04.002     Document Type: Article

References (34)

1. WHO Prevalence of diabetes worldwide 2007, WHO, Geneva.
2. CDC Diabetes surveillance 2007, HHS, Atlanta, GA.
3. Duncan B.B., Schmidt M.I. The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther 2006, 8(1):7-17.
4. Galan P., de Bree A., Mennen L., Potier de Courcy G., Preziozi P., Bertrais S., et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging 2003, 7:428-435.
5. Slatter D.A., Bolton C.H., Bailey A.J. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000, 43:550-557.
6. Vollset S.E., Refsum H., Tverdal A., Nygard O., Nordrehaug J.E., Tell G.S., et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001, 74:130-136.
7. Rosato R., Ciccone G., Bo S., Pagano G.F., Merletti F., Gregori D. Evaluating cardiovascular mortality in type 2 diabetes patients: an analysis based on competing risks Markov chains and additive regression models. J Eval Clin Pract 2007, 13:422-428.
8. De Caterina R., Madonna R., Bertolotto A., Schmidt E.B. n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 2007, 30:1012-1026.
9. Mahan, L.K., Escott-Stump, S. Krause's food, Nutrition and diet therapy. 11th ed. Nutrition in cardiovascular disease. Philadelphia, PA; 2005, 592 p.
10. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
11. Lopez-Garcia E., Schulze M.B., Manson J.E., Meigs J.B., Albert C.M., Rifai N., et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004, 134:1806-1811.
12. Madsen T., Skou H.A., Hansen V.E., Fog L., Christensen J.H., Toft E., et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 2001, 88:1139-1142.
13. Frenoux J.M., Prost E.D., Belleville J.L., Prost J.L. A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr 2001, 131:39-45.
14. Wander R.C., Du S.H. Oxidation of plasma proteins is not increased after supplementation with eicosapentaenoic and docosahexaenoic acids. Am J Clin Nutr 2000, 72:731-737.
15. Li D., Yu X.M., Xie H.B., Zhang Y.H., Wang Q., Zhou X.Q., et al. Platelet phospholipid n-3 PUFA negatively associated with plasma homocysteine in middle-aged and geriatric hyperlipaemia patients. Prostaglandins Leukot Essent Fatty Acids 2007, 76:293-297.
16. Nettleton J.A., Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005, 105(3):428-440.
17. Richard M.J., Portal B., Meo J., Coudray C., Hadjian A., Favier A. Malondialdehyde kit evaluated for determining plasma and lipoprotein fractions that react with thiobarbituric acid. Clin Chem 1992, 38:704-709.
18. *Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-191.
19. Signorello M.G., Segantin A., Passalacqua M., Leoncini G. Homocysteine decreases platelet NO level via protein kinase C activation. Nitric Oxide 2009, 20(2):104-113.
20. Antoniades C., Antonopoulos A.S., Tousoulis D., Marinou K., Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009, 30:6-15.
21. Severus W.E., Littman A.B., Stoll A.L. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 2001, 9(6):280-293.
22. Berstad P., Konstantinova S.V., Refsum H., Nurk E., Vollset S.E., Tell G.S., et al. Dietary fat and plasma total homocysteine concentrations in 2 adult age groups: the Hordaland Homocysteine Study. Am J Clin Nutr 2007, 85:1598-1605.
23. Piolot A., Blache D., Boulet L., Fortin L.J., Dubreuil D., Marcoux C., et al. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med 2003, 141:41-49.
24. Durand P., Prost M., Loreau N., Lussier-Cacan S., Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001, 81:645-672.
25. Saedisomeolia A., Wood G.L., Garg M.L., Gibson G.P., Wark A.B.P. Supplementation of long chain n-3 polyunsaturated fatty acids increases the utilization of lycopene in cultured airway epithelial cells. J Food Lipids 2008, 15:421-432.
26. Li D., Mann N.J., Sinclair A.J. A significant inverse relationship between concentrations of plasma homocysteine and phospholipid docosahexenoic acid in healthy male subjects. Lipids 2006, 41(1):85-89.
27. Zeman M., Zak A., Vecka M., Tvrzicka E., Pisarikova A., Stankova B. Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination. Cas Lek Cesk 2005, 144:737-741.
28. Baro L., Fonolla J., Pena J.L., Martinez-Ferez A., Lucena A., Jimenez J., et al. n-3 Fatty acids plus oleic acid and vitamin supplemented milk consumption reduces total and LDL cholesterol, homocysteine and levels of endothelial adhesion molecules in healthy humans. Clin Nutr 2003, 22:175-182.
29. Faschinger C., Schmut O., Wachswender C., Mossbock G. Glaucoma and oxidative stress. Determination of malondialdehyde - a product of lipid peroxidation. Ophthalmologe 2006, 103:953-959.
30. Iraz M., Erdogan H., Ozyurt B., Ozugurlu F., Ozgocmen S., Fadillioglu E. Brief communication: omega-3 essential fatty acid supplementation and erythrocyte oxidant/antioxidant status in rats. Ann Clin Lab Sci 2005, 35:169-173.
31. Vaagenes H., Muna Z.A., Madsen L., Berge R.K. Low doses of eicosapentaenoic acid, docosahexaenoic acid, and hypolipidemic eicosapentaenoic acid derivatives have no effect on lipid peroxidation in plasma. Lipids 1998, 33:1131-1137.
32. Brude I.R., Drevon C.A., Hjermann I., Seljeflot I., Lund-Katz S., Saarem K., et al. Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants. Arterioscler Thromb Vasc Biol 1997, 17:2576-2588.
33. Murray R.K., Granner D.K., Mayes P.A., Rodwell V.W. Harper's Illustrated biochemistry 2006, McGraw-Hill. 27th ed.
34. Billups K.L., Kaiser D.R., Kelly A.S., Wetterling R.A., Tsai M.Y., et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003, 15:231-236.